NCT05354336View on ClinicalTrials.gov

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

August 24, 2019

Study Completion Date

August 24, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

SHR6390(100mg)

SHR6390 at a single oral dose of 100 mg.

DRUG

SHR6390(125mg)

SHR6390 at a single oral dose of 125 mg.

DRUG

SHR6390(150mg)

SHR6390 at a single oral dose of 150 mg.

Trial Locations (1)

266003

Phase I Clinical Research Center, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER

NCT05354336 - A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers | Biotech Hunter | Biotech Hunter